How does ICE Bioscience reduce IP and know-how risks when sponsors transfer proprietary compounds and assay designs?

ICE Bioscience builds discovery campaigns on internal platform technologies, including ICESTP Safety Panels and ICECP and KRAS cancer cell panels, which reduces the need for sponsors to transfer proprietary assay architectures or cell assets. ICESTP uses predefined target sets aligned with Bowes-44 and Safety-77 literature, and ICECP uses an internal bank of more than 600 tumor cell lines, over 100 engineered and resistant lines, and more than 500 human tumor cell lines for panel construction.

How does ICE Bioscience address assay reproducibility and false-positive or false-negative risk?

ICESTP Safety Panels 44 and 77 are functional secondary pharmacology panels run in both single-concentration and full dose–response modes with potency estimation. All kinase targets are profiled at 1 mM ATP, and reports include radar plots and concentration–effect curves, allowing sponsors to evaluate consistency and confirm pharmacology across targets.

How does ICE Bioscience support raw data transparency and secondary pharmacology data integrity?

ICESTP outputs include full dose–response data, numerical effect tables, and graphical plots for each target, giving sponsors visibility from primary response values through to IC50 or EC50 metrics. The panels are aligned with published Bowes-44 and Safety-77 recommendations, which provide an external reference for target selection and data structure.

How does ICE Bioscience limit variability in high-throughput screening compared with manual offshore setups?

ICE Bioscience operates a joint automated laboratory with SPT Labtech in Beijing that integrates firefly liquid handling into high-throughput screening and assay development workflows. Firefly supports non-contact positive displacement dispensing over nanoliter to milliliter ranges in 96-well and 384-well formats and is used for 2D and 3D viability, clonogenic, and panel assays, reducing operator and plate-to-plate variability.

How does ICE Bioscience align safety pharmacology services with Western regulatory expectations?

ICESTP Safety Panel 44 is described as aligned with historical Bowes-44 off-target selection and ICH expectations, and ICESTP Safety Panel 77 is described as aligned with the industry Safety-77 framework for secondary pharmacology. The ICESTP Drug Abuse Safety Panel follows FDA recommendations for assessing drug abuse potential with 55 CNS targets and 101 assays.

Unlock Next-Gen Oncology Therapies with Us at AACR D3 2026 - Events - Drug Discovery CRO Services | Target Validation to Preclinical

Unlock Next-Gen Oncology Therapies with Us at AACR D3 2026

DATE:2026-07-10

What's reshaping the landscape of oncology therapeutics? Across novel modalities, targeted therapies and drug resistance research, breakthroughs keep emerging rapidly.

We are heading to AACR Drug Discovery and Development (AACR D3) in Boston, where we'll present three scientific posters featuring our latest advances on transformative platforms and approaches in oncology discovery:

✅ RIPTAC platform linking target engagement to selective cancer cell killing
✅ Drug-resistant cell panel for ADC & KRAS resistance solutions

Join us at Booth #8 and dive into our featured posters. Let's discuss how our integrated drug discovery platform can accelerate your programs.

Location: Sheraton Boston Hotel, Boston, Massachusetts

Date: July 21-24, 2026

Booth: #8

PREV：Reshaping the Future of Modern Drug Disc...

NEXT：There's no more

RELEVANT NEWS

Reshaping the Future of Modern...
2026-06-15
Join Our Expert Live Presentat...
2026-05-29
Shaping the Next Era of Precis...
2026-05-28
Advancing Next-Gen Therapeutic...
2026-05-19

Contact Us

We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.

Target Based Assays

Cell Based Assays

Featured Services

In Vitro Safety Assessment

In Vitro Immunology Assays

In Vivo Pharmacology

DMPK

NEWS

Unlock Next-Gen Oncology Therapies with Us at AACR D3 2026

RELEVANT NEWS

Contact Us